Pablo de la Cueva ha participado como asesor y/o investigador y/o ponente con los siguientes laboratorios farmacuticos: Abbvie, Almirall, BMS, Boehringer-Ingelheim, Celgene, Janssen Cilag, LEO Pharma, Lilly, MSD, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi y UCB
The present study ACHIEVE-3 was a 52-week, non-inferiority, open-label, active-control, randomised, phase 3 trial comparing orforglipron 12 mg or 36 mg versus oral semaglutide 7 mg or 14 mg (Rosenstock et al, 2026)
Without enough water, your body cant efficiently remove waste, which may lead to bloating, sluggishness, and even stalled weight loss progress
Profile of Plasma Angiogenic Factors before and after Hepatectomy for Colorectal Cancer Liver Metastases
Jun Feng, University of Wisconsin-Madison, United States Updates Copyright 2021 Saini, Kashyap, Bindal, Saini and Gupta